- Home
- GEG vs ICCM Comparison
GEG vs ICCM Comparison
Compare GEG & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GEG
- ICCM
- Stock Information
- Founded
- GEG 1994
- ICCM 2006
- Country
- GEG United States
- ICCM Israel
- Employees
- GEG N/A
- ICCM N/A
- Industry
- GEG Computer Software: Prepackaged Software
- ICCM
- Sector
- GEG Technology
- ICCM
- Exchange
- GEG Nasdaq
- ICCM Nasdaq
- Market Cap
- GEG 60.4M
- ICCM 59.9M
- IPO Year
- GEG N/A
- ICCM N/A
- Fundamental
- Price
- GEG $2.07
- ICCM $1.05
- Analyst Decision
- GEG
- ICCM Strong Buy
- Analyst Count
- GEG 0
- ICCM 1
- Target Price
- GEG N/A
- ICCM $2.50
- AVG Volume (30 Days)
- GEG 9.8K
- ICCM 320.9K
- Earning Date
- GEG 08-28-2025
- ICCM 08-19-2025
- Dividend Yield
- GEG N/A
- ICCM N/A
- EPS Growth
- GEG N/A
- ICCM N/A
- EPS
- GEG N/A
- ICCM N/A
- Revenue
- GEG $19,626,000.00
- ICCM $3,273,000.00
- Revenue This Year
- GEG N/A
- ICCM $83.41
- Revenue Next Year
- GEG N/A
- ICCM $185.02
- P/E Ratio
- GEG N/A
- ICCM N/A
- Revenue Growth
- GEG 64.34
- ICCM 0.34
- 52 Week Low
- GEG $1.70
- ICCM $0.48
- 52 Week High
- GEG $2.33
- ICCM $1.66
- Technical
- Relative Strength Index (RSI)
- GEG 44.46
- ICCM 49.78
- Support Level
- GEG $1.96
- ICCM $0.96
- Resistance Level
- GEG $2.15
- ICCM $1.03
- Average True Range (ATR)
- GEG 0.09
- ICCM 0.07
- MACD
- GEG -0.02
- ICCM 0.01
- Stochastic Oscillator
- GEG 29.73
- ICCM 90.91
About GEG Great Elm Group Inc.
Great Elm Group Inc operates as an alternative asset manager focused on growing a scalable and diversified portfolio of long-duration and permanent capital vehicles across credit, real estate, specialty finance, and other alternative strategies. Along with its subsidiaries, it manages Great Elm Capital Corp, a publicly traded business development company, and Monomoy Properties REIT, LLC, an industrial-focused real estate investment trust, in addition to other investments.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.